Log in

Relevant bibliographies by topics / [74.4%] survived with 18 / Journal articles

To see the other types of publications on this topic, follow the link: [74.4%] survived with 18.

Journal articles on the topic '[74.4%] survived with 18'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '[74.4%] survived with 18.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Choueiri, Toni K., Wanling Xie, Lauren Christine Harshman, et al. "Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy (TT): Results from the International mRCC Database Consortium." Journal of Clinical Oncology 30, no. 5_suppl (2012): 358. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.358.

Full text

Abstract:

358 Background: Survival estimates for patients with mRCC are traditionally reported from the time of TT initiation. These survival projections, however, may not be applicable to patients who have already survived a period of time after initiating therapy. CS accounts for elapsed time since starting therapy, providing more relevant prognostic information. Methods: Data on 1673 patients treated with first-line VEGF TT between 4/7/2003 and 10/12/2010 was analyzed. Median follow up for patients still alive is 20.1 months. Conditioned survival was calculated on the set of patients alive or on TT a

APA, Harvard, Vancouver, ISO, and other styles

2

Santschi, Elizabeth M., Donnie E. Slone, R. Gronwall, James S. Juzwiak, and H. David Moll. "Types of colic and frequency of postcolic abortion in pregnant mares: 105 cases (1984 - 1988)." Journal of the American Veterinary Medical Association 199, no. 3 (1991): 374–77. http://dx.doi.org/10.2460/javma.1991.199.03.374.

Full text

Abstract:

Summary The records of 105 pregnant mares and 105 nonpregnant horses with colic admitted to an equine hospital were reviewed. The 2 groups had similar types of colic and short-term survivability. Of the 105 pregnant mares, 31 were treated medically and 74 required surgical intervention. Thirty-three of the 105 mares died or were euthanatized. Thirteen (18%) of the 72 remaining mares aborted. Of 4 mares with severe medical cases, 2 died, 1 aborted, and 1 aborted and died. Of 27 horses with medical cases that required less intensive treatment, none died and 2 aborted. Of the 74 horses that requi

APA, Harvard, Vancouver, ISO, and other styles

3

Wadhwa, Roopma, Takashi Taketa, Arlene M. Correa, et al. "Incidence of brain metastases following trimodality therapy (TMT) in patients with esophageal and gastroesophageal (E-EGCJ) cancer." Journal of Clinical Oncology 31, no. 4_suppl (2013): 108. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.108.

Full text

Abstract:

108 Background: Brain metastases in E-EGJ cancer patients following TMT are considered rare. We reviewed the cumulative incidence of brain metastases in a large cohort of patients who underwent TMT and had a long follow-up. Methods: Data were analyzedretrospectively for 579 E-EGJ cancer patients who underwent TMT between years 2000 and 2010. None had screening or surveillance brain imaging. Results: Median follow-up time was 57.4 months (95% confidence interval [CI]: 51.5-63.3 months). Common patient characteristics were as follows: median age: 59.5 years (range, 39-74 years), Caucasian ethnic

APA, Harvard, Vancouver, ISO, and other styles

4

Bojanini Molina, Leyla, Muhamad Alhaj Moustafa, Ricardo Daniel Parrondo, et al. "Hepatosplenic T-cell lymphoma: The Mayo Clinic experience." Journal of Clinical Oncology 38, no. 15_suppl (2020): e20036-e20036. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e20036.

Full text

Abstract:

e20036 Background: Hepatosplenic T cell lymphoma (HSTL) is a rare subtype of mature T cell lymphomas accounting for less than 1 percent of non-Hodgkin lymphomas. it has been associated with poor prognosis. It typically involves sinusoids in the spleen, liver, and bone marrow. Methods: Following IRB approval, we retrospectively evaluated patients with HSTL treated at the Mayo Clinic Cancer Center 1996-2019. Kaplan-Meier survival analysis and univariate analysis to identify prognostic factors were performed. We investigated clinical characteristics and outcomes among patients with HSTL. Results:

APA, Harvard, Vancouver, ISO, and other styles

5

Aytac, Selin, Inci Yaman Bajin, Barış Kuşkonmaz, et al. "Infant Lymphoblastic Leukemia: A Single Center Experience." Blood 128, no. 22 (2016): 5161. http://dx.doi.org/10.1182/blood.v128.22.5161.5161.

Full text

Abstract:

Abstract Infantacute lymphoblastic leukemia (ALL) is a rare disease and consist of 4-5% of all childhood ALL. Despite improved survival rates of childhood ALL, infants with ALL have a worse prognosis . There were 206 patients diagnosed with ALL at Hacettepe University, Pediatric Hematology Department between 1 January 2008 and 31 December 2016, 11 out of 206 (5.3%) were diagnosed as infant ALL. We aimed to evaluate clinical findings, laboratory results and treatment outcome of our infant ALL patients retrospectively. There were 9 boys and two girls with a median age of 8 months (range 1-12 mon

APA, Harvard, Vancouver, ISO, and other styles

6

Sabet, Amir, Martin Ries, Yamen Al-Khalaf, et al. "Early metabolic response assessment of breast cancer liver metastases: 4-week posttreatment FDG PET predicts survival after 90Y microsphere radioembolization." Nuklearmedizin 58, no. 03 (2019): 242–48. http://dx.doi.org/10.1055/a-0891-7650.

Full text

Abstract:

Abstract Aim To evaluate the feasibility of early metabolic response assessment with 18F-FDG PET/CT in patients with breast cancer liver metastases 4 weeks after radioembolization with Yttrium-90 labeled microspheres. Methods 25 patients (mean age 58y, range 40–74) with advanced stage liver metastases of breast cancer were treated with 1.9 ± 0.4 GBq of 90Y-microspheres in the salvage setting and underwent 18F-FDG PET/CT at baseline and 4 weeks post-radioembolization. 14 patients (56 %) had an excessive hepatic tumor burden (> 50 % of total liver volume), 21 patients (84 %) had extrahepatic

APA, Harvard, Vancouver, ISO, and other styles

7

Marino, Dominic J., David T. Matthiesen, Joseph D. Stefanacci, and Scott D. Moroff. "Evaluation of dogs with digit masses: 117 cases (1981–1991)." Journal of the American Veterinary Medical Association 207, no. 6 (1995): 726–28. http://dx.doi.org/10.2460/javma.1995.207.06.0726.

Full text

Abstract:

Summary Medical records of 117 dogs with digit masses were reviewed. Of 124 digit masses, 76 (61%) were malignant neoplasms, 25 (20%) were benign neoplasms, and 23 (19%) were pyogranulomatous inflammation. Of 29 digits with radiographic evidence of bone lysis, 24 (83%) were affected by malignant masses, whereas only 5 of 29 (17%) digits with radiographic evidence of bone lysis were affected by benign or pyogranulomatous masses. Only 1 of 19 (5%) dogs with melanoma had radiographic evidence of lysis, but 20 of 25 (80%) dogs with squamous cell carcinoma had radiographic evidence of bone lysis. T

APA, Harvard, Vancouver, ISO, and other styles

8

Marcic, Dejan, Irena Ogurlic, Slavka Mutavdzic, and Pantelija Peric. "The effect of spiromesifen on the reproductive potential of Tetranychus urticae koch (Acari: Tetranychidae)." Pesticidi i fitomedicina 24, no. 3 (2009): 203–9. http://dx.doi.org/10.2298/pif0903203m.

Full text

Abstract:

Laboratory bioassays were conducted to evaluate the effects of spiromesifen on the fecundity, fertility and population growth of two-spotted spider mite (Tetranychus urticae Koch) after treatment of pre-ovipositing females with five acaricide concentrations: 180 mg/l (maximum recommended concentration for use in glasshouses against spider mites), 18 mg/l, 1.8 mg/l and 0.18 mg/l (the last one was discriminative for eggs and immatures in preliminary studies, i.e. produced 100% mortality of those stages) and 0.018 mg/l. After 24h exposure, the percentages of females surviving treatment without vi

APA, Harvard, Vancouver, ISO, and other styles

9

Schmidt, Mary Lou, Ashutosh Lal, Robert C. Seeger, et al. "Favorable Prognosis for Patients 12 to 18 Months of Age With Stage 4 Nonamplified MYCN Neuroblastoma: A Children's Cancer Group Study." Journal of Clinical Oncology 23, no. 27 (2005): 6474–80. http://dx.doi.org/10.1200/jco.2005.05.183.

Full text

Abstract:

Purpose The long-term survival of children between age 12 and 24 months with stage 4 neuroblastoma and nonamplified MYCN (MYCN-NA) has not been defined previously. Patients and Methods Survival for stage 4 MYCN-NA neuroblastoma patients enrolled onto Children's Cancer Group (CCG) protocols 321P2 (1986 to 1991) and 3891 (1991 to 1996) was analyzed. Treatment consisted of intensive alkylator-based induction chemotherapy with or without autologous bone marrow transplantation (ABMT) with or without 13 cis-retinoic acid. Survival was analyzed by age strata less than 12, 12 to 18, 18 to 24, and more

APA, Harvard, Vancouver, ISO, and other styles

10

Dao, Vi, Morel Rubinger, Eric J. Bow, et al. "Epidemiology of Adult Acute Lymphoblastic Leukemia in Manitoba, Canada: Does This Approximate Clinical Trial Data?." Blood 106, no. 11 (2005): 4554. http://dx.doi.org/10.1182/blood.v106.11.4554.4554.

Full text

Abstract:

Abstract Background: Outcomes of unselected adult ALL patients (pts) have not been well studied at a population level. Whether such pts behave differently to those in formal clinical trials is unclear. We developed a uniform therapeutic protocol as the provincial standard of care in Manitoba, a province with 1.2 million people, for adult pts since 1989 (“ALL89-1”). The aim of this retrospective study was: to ascertain the local epidemiology of adult ALL; to analyze the efficacy and toxicity of the ALL89-1 regimen and any other regimens given to pts in a population-based setting. Methods: All p

APA, Harvard, Vancouver, ISO, and other styles

11

Staunton, M. D., D. M. Melville, A. Monterrosa, and J. M. Thomas. "A 25-Year Prospective Study of Modified Radical Mastectomy (Patey) in 193 Patients." Journal of the Royal Society of Medicine 86, no. 7 (1993): 381–84. http://dx.doi.org/10.1177/014107689308600704.

Full text

Abstract:

The results of a prospective study over 20 years of 193 patients with breast carcinoma treated by Patey mastectomy are presented together with details of the operative technique employed. One hundred and twenty-eight cases (66%) were stage 1 ( T1/ T2 N0), 46 (24%) were stage 2 ( T1/ T2 N1), 18 (9%) were stage 3 ( T3 N0/ N1) and one was stage 4 (M1). The probability of survival together with 95% confidence intervals for stage 1 ( T1/ T2 N0) at 10 years was 79% (71–88); and at 15 years 74% (61–87). For stage 2 ( T1/ T2 N1), the probability of survival at 10 years was 64% (48–79), and at 15 years

APA, Harvard, Vancouver, ISO, and other styles

12

Thiel, U., S. J. Schober, A. Ranft, et al. "No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease." Bone Marrow Transplantation 56, no. 7 (2021): 1550–57. http://dx.doi.org/10.1038/s41409-020-01200-x.

Full text

Abstract:

AbstractPatients with advanced Ewing sarcoma (AES) carry a poor prognosis. Retrospectively, we analyzed 66 AES patients treated with allogeneic stem cell transplantation (allo-SCT) receiving HLA-mismatched (group A, n = 39) versus HLA-matched grafts (group B, n = 27). Median age at diagnosis was 13 years, and 15 years (range 3–49 years) at allo-SCT. The two groups did not differ statistically in distribution of gender, age, remission status/number of relapses at allo-SCT, or risk stratum. 9/39 (23%) group A versus 2/27 (7%) group B patients developed severe acute graft versus host disease (GvH

APA, Harvard, Vancouver, ISO, and other styles

13

Ko, A. H., M. A. Tempero, Y. Shan, et al. "A multinational phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer." Journal of Clinical Oncology 29, no. 4_suppl (2011): 237. http://dx.doi.org/10.1200/jco.2011.29.4_suppl.237.

Full text

Abstract:

237 Background: PEP02 is a novel nanoparticle liposome formulation of irinotecan (CPT-11) that has improved pharmacokinetics and tumor biodistribution of both CPT-11 and its active metabolite-SN38 compared to the free form drug. PEP02 has showed encouraging safety and efficacy in various tumor types, including significant antitumor activity in a human pancreatic cancer L3.6pl orthotopic nude mouse xenograft model. In previous phase I studies, PEP02 either alone or in combination with 5-FU/LV demonstrated prolonged disease control in 5 of 7 (71%) patients (pts) with gemcitabine (GEM)-refractory

APA, Harvard, Vancouver, ISO, and other styles

14

Blackstock, A. W., M. A. Socinski, J. Bogart, et al. "Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105." Journal of Clinical Oncology 24, no. 18_suppl (2006): 7042. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7042.

Full text

Abstract:

7042 Background: Combined chemoradiotherapy is the standard of care in stage III NSCLC. At standard TRT doses, local failures remain problematic and strategies exploiting the dose-response aspect of TRT are warranted. 3-D TRT allows escalation of TRT dose with acceptable toxicity (Socinski et al, J Clin Oncol 22:4341, 2004) and may enhance survival by improving loco-regional control. Methods: This is a two-arm randomized phase II trial evaluating 74 Gy with Con chemotherapy: Arm A- 2 cycles of Ind carboplatin (C) (AUC 6) and paclitaxel (P) (225 mg/m2) followed by weekly Con C (AUC 2/wk) and P

APA, Harvard, Vancouver, ISO, and other styles

15

Chang, Yongjian, and Barbara M. Reed. "Preculture Conditions Influence Cold Hardiness and Regrowth of Pyrus cordata Shoot Tips After Cryopreservation." HortScience 36, no. 7 (2001): 1329–33. http://dx.doi.org/10.21273/hortsci.36.7.1329.

Full text

Abstract:

Cold hardiness and cryogenic survival of micropropagated pear (Pyrus cordata Desv.) shoots were evaluated after pretreatments with ABA and sucrose. Shoot cold hardiness increased by 3 °C, and cryopreserved shoot tip growth increased by 17% after a 4-week 150 μm ABA pretreatment. Low temperature (LT) pretreatments improved the recovery of cryopreserved P. cordata shoot tips. Six to 10 weeks of LT were required for reaching high cryopreservation recovery. ABA and LT treatments produced significant synergistic effects on both cold hardiness and cryopreservation recovery. ABA shortened the LT requ

APA, Harvard, Vancouver, ISO, and other styles

16

Spina, Michele, Cecilia Simonelli, Emanuela Vaccher, et al. "Long-Term Follow-up of Rituximab and Infusional Cyclophosphamide, Doxorubicin, and Etoposide (cde) in Combination with HAART in HIVRelated Non-Hodgkin’s Lymphomas (NHL)." Blood 112, no. 11 (2008): 1467. http://dx.doi.org/10.1182/blood.v112.11.1467.1467.

Full text

Abstract:

Abstract Background: The combination of Rituximab plus chemotherapy (CT) is more effective than CT alone in the treatment of high grade NHL. Objective: To report the long-term follow-up of CDE plus Rituximab in HIV-NHL. Methods: In June 1998, we started a phase II study using infusional CDE (Cyclophosphamide 187.5 mg/m2/day, Doxorubicin 12.5 mg/m2/day and Etoposide 60 mg/m2/day) administered by continuous intravenous infusion for 4 days every 4 weeks and Rituximab 375 mg/m2 i.v. on day 1. HAART was given concomitantly with CT. Results: Seventy-four patients (pts) have been enrolled. The median

APA, Harvard, Vancouver, ISO, and other styles

17

Spina, Michele, Ulrich Jaeger, Joseph A. Sparano, et al. "Long-Term Follow-up of Rituximab and Infusional Cyclophosphamide, Doxorubicin, and Etoposide (CDE) In Combination with HAART In HIV-Related Non-Hodgkin's Lymphomas (NHL)." Blood 116, no. 21 (2010): 5072. http://dx.doi.org/10.1182/blood.v116.21.5072.5072.

Full text

Abstract:

Abstract Abstract 5072 Background: The combination of Rituximab plus chemotherapy (CT) is more effective than CT alone in the treatment of high grade NHL. Objective: To report the long-term follow-up of CDE plus Rituximab in HIV-NHL. Methods: In June 1998, we started a phase II study using infusional CDE (Cyclophosphamide 187.5 mg/m2/day, Doxorubicin 12.5 mg/m2/day and Etoposide 60 mg/m2/day) administered by continuous intravenous infusion for 4 days every 4 weeks and Rituximab 375 mg/m2 i.v. on day 1. HAART was given concomitantly with CT. Results: Seventy-four patients (pts) have been enroll

APA, Harvard, Vancouver, ISO, and other styles

18

Dean, Robert M., John W. Sweetenham, Tao Jin, et al. "Risk Factors and Outcomes for Relapse after Autologous Stem Cell Transplantation for Hodgkin Lymphoma." Blood 110, no. 11 (2007): 1903. http://dx.doi.org/10.1182/blood.v110.11.1903.1903.

Full text

Abstract:

Abstract Despite successful outcomes for many patients (pts) with relapsed or refractory Hodgkin lymphoma, disease recurrence leads to a significant number of treatment failures after high-dose chemotherapy with autologous stem cell transplantation (ASCT). Using a prospectively maintained database, a retrospective analysis was conducted in 245 consecutive pts who underwent ASCT for Hodgkin lymphoma from 1985 through 2005 at the Cleveland Clinic Foundation. Objectives were to identify risk factors and outcomes associated with early relapse (within 1 year post ASCT) versus late relapse (over 1 y

APA, Harvard, Vancouver, ISO, and other styles

19

Atkins, Michael B., John M. Kirkwood, Jedd D. Wolchok, et al. "Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma." Journal of Clinical Oncology 37, no. 15_suppl (2019): 9533. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.9533.

Full text

Abstract:

9533 Background: We previously reported a 3-year overall survival (OS) rate of 63% with NIVO+IPI concurrent therapy in the initial phase I dose-escalation study for the combination, conducted in patients (pts) with advanced melanoma. Here, we report OS after 5 years of overall study follow-up and assess survival rates after stopping treatment. Methods: Adults with previously treated or untreated unresectable stage III or IV melanoma, and ECOG performance status of 0 or 1, received NIVO + IPI Q3W × 4 as mg/kg in one of the following cohorts: (1) NIVO 0.3 + IPI 3; (2) NIVO 1 + IPI 3; (2a) NIVO 3

APA, Harvard, Vancouver, ISO, and other styles

20

Lugtenburg, Pieternella Johanna, Peter de Nully Brown, Bronno van der Holt, et al. "Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)." Journal of Clinical Oncology 38, no. 29 (2020): 3377–87. http://dx.doi.org/10.1200/jco.19.03418.

Full text

Abstract:

PURPOSE Immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for patients with diffuse large B-cell lymphoma (DLBCL). This randomized trial assessed whether rituximab intensification during the first 4 cycles of R-CHOP could improve the outcome of these patients compared with standard R-CHOP. PATIENTS AND METHODS A total of 574 patients with DLBCL age 18 to 80 years were randomly assigned to induction therapy with 6 or 8 cycles of R-CHOP-14 with (RR-CHOP-14) or without (R-CHOP-14) intensification of rituximab in

APA, Harvard, Vancouver, ISO, and other styles

21

Hügli, A., D. Moro, B. Mermillod, et al. "Phase II Trial of Up-Front Accelerated Thoracic Radiotherapy Combined With Chemotherapy and Optional Up-Front Prophylactic Cranial Irradiation in Limited Small-Cell Lung Cancer." Journal of Clinical Oncology 18, no. 8 (2000): 1662–67. http://dx.doi.org/10.1200/jco.2000.18.8.1662.

Full text

Abstract:

PURPOSE: To investigate the feasibility and outcome of bifractionated, up-front thoracic radiotherapy (TR) (45 Gy in 30 fractions of 1.5 Gy twice daily over 3 weeks) combined with chemotherapy (CT) (six cycles of cisplatin and etoposide) and optional low-dose, up-front prophylactic cranial irradiation (18 Gy in 10 fractions of 1.8 Gy twice daily over 5 days) in limited small-cell lung cancer. PATIENTS AND METHODS: CT (etoposide 100 mg/m2 for 3 days and cisplatin 25 mg/m2 for 3 days) was started on day 8 or 15 after the first TR treatment. In the five subsequent cycles, cisplatin was given as a

APA, Harvard, Vancouver, ISO, and other styles

22

Wang, Dongying, Chunhua Zhao, Li Fu, Yang Liu, Weiyang Zhang, and Tianmin Xu. "Primary Clear Cell Adenocarcinoma of the Cervix: A Clinical Analysis of 18 Cases without Exposure to Diethylstilbestrol." Obstetrics and Gynecology International 2019 (March 26, 2019): 1–6. http://dx.doi.org/10.1155/2019/9465375.

Full text

Abstract:

Objectives. Cervical clear cell adenocarcinoma (CCAC) is a rare malignant tumor with independent biological behavior in the female reproductive system. In this report, we collect the clinical and histopathological characteristics of 18 CCAC patients without exposure to diethylstilbestrol (DES) and conduct relevant clinical analysis. Methods. We retrospectively analyzed the clinical data of 18 patients with CCAC who were diagnosed and treated from January 2009 to August 2017 in the Second Hospital of Jilin University. Results. A total of 18 patients were enrolled. The age of patients ranged fro

APA, Harvard, Vancouver, ISO, and other styles

23

Tseng, Li-Jung, Hsi-Yu Yu, Chih-Hsien Wang, et al. "Impact of Age-Adjusted Charlson Comorbidity on Hospital Survival and Short-Term Outcome of Patients with Extracorporeal Cardiopulmonary Resuscitation." Journal of Clinical Medicine 7, no. 10 (2018): 313. http://dx.doi.org/10.3390/jcm7100313.

Full text

Abstract:

Extracorporeal cardiopulmonary resuscitation (ECPR) has gradually come to be regarded as an effective therapy, but the hospital mortality rate after ECPR is still high and unpredictable. The present study tested whether age-adjusted Charlson comorbidity index (ACCI) can be used as an objective selection criterion to ensure the most efficient utilization of medical resources. Adult patients (age ≥ 18 years) receiving ECPR at our institution between 2006 and 2015 were included. Data regarding ECPR events and ACCI characteristics were collected immediately after the extracorporeal membrane oxygen

APA, Harvard, Vancouver, ISO, and other styles

24

Richards, J., A. Testori, E. Whitman, et al. "Autologous tumor-derived HSPPC-96 vs. physician’s choice (PC) in a randomized phase III trial in stage IV melanoma." Journal of Clinical Oncology 24, no. 18_suppl (2006): 8002. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.8002.

Full text

Abstract:

8002 Background: Vitespen (Oncophage; formerly HSPPC-96) is an autologous, tumor-derived, heat shock protein (gp96)-peptide complex vaccine that has shown signals of clinical activity in patients (pts) with metastatic melanoma, and colon and renal cancers. Methods: This phase 3 trial compares vitespen v. PC in AJCC stage IV melanoma. Pts had ECOG PS 0/1 and ≥7 g tumor tissue for vaccine production. Randomization was 2:1 favoring vitespen, and stratified by ECOG PS and AJCC substage (M1a, -b, -c). Vitespen was administered s.c. weekly for 4 weeks, then biweekly until vaccine depletion or diseas

APA, Harvard, Vancouver, ISO, and other styles

25

Pan, Zhenyu, Guozi Yang, Hua He, et al. "Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase I/II study." Therapeutic Advances in Medical Oncology 12 (January 2020): 175883592093795. http://dx.doi.org/10.1177/1758835920937953.

Full text

Abstract:

Purpose: A phase I/II study of intrathecal pemetrexed (IP) combined with involved-field radiotherapy (IFRT) was performed to determine feasibility, safety, and antitumor activity for leptomeningeal metastases (LM) from solid tumors. Methods: Participants first received induction IP administration, followed by concomitant radiotherapy within 3 days. The concomitant regimen consisted of IP (pemetrexed 10 mg, dexamethasone 5 mg, once per week, 4 times in 4 weeks) and IFRT (40 Gy in 20 fractions). Six participants were recruited to assess feasibility in phase I, and then 28 patients were recruited

APA, Harvard, Vancouver, ISO, and other styles

26

Pasini, F., G. de Manzoni, L. Stievano, et al. "Effect of neoadjuvant combined modality therapy with weekly docetaxel (D) and cisplatin (P), 5-fluorouracil (5-FU) continuous infusion (c.i.), and concurrent radiotherapy (RT) on pathological response rate in esophageal cancers (EC): A phase II study." Journal of Clinical Oncology 27, no. 15_suppl (2009): 4548. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.4548.

Full text

Abstract:

4548 Background: The achievement of pathological complete response (pCR) seems essential to improve survival in EC. In a phase I study (Pasini et al, Ann Oncol 2005) we demonstrated the feasibility of a novel protocol of neoadjuvant chemoradiation. Based on these promising results, we have performed a phase II study. The primary end point was the pathological response rate, the secondary end points were survival and toxicity. Methods: 74 pts with stage II-III EC (37 adenocarcinomas) were enrolled; median age was 59 yrs (42–73). Treatment consisted of D 35 mg/m2 and P 25 mg/m2 d 1,8,15,29,36,43

APA, Harvard, Vancouver, ISO, and other styles

27

O'Brien, Mary, Rabab Mohamed Gaafar, Sanjaykumar Popat, et al. "Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052." Journal of Clinical Oncology 30, no. 15_suppl (2012): 7081. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.7081.

Full text

Abstract:

7081 Background: Cisplatin is one of the most active drugs available in MPM while bortezomib has shown some activity in single agent phase II studies against MPM. This was a prospective phase II study of cisplatin and bortezomib (CB) in the first line treatment of MPM. Methods: Patients with histological proven MPM, with performance status (PS) 0/1, were eligible. The doses were cisplatin 75mg/m2 /3 wks and bortezomib 1.3mg/m2 day 1, 4, 8, 11 every 3 wks. The primary end-point was progression free survival rate at 18 wks (PFSR=18). The 2-stage Simon design (a=0.1; b = 0.05, P0=0.50 and P1=0.67

APA, Harvard, Vancouver, ISO, and other styles

28

Kazarinov, D. N., and M. Yu Kirov. "Clinical case of lightning injury." Messenger of ANESTHESIOLOGY AND RESUSCITATION 20, no. 6 (2023): 74–79. http://dx.doi.org/10.24884/2078-5658-2023-20-6-74-79.

Full text

Abstract:

Atmospheric electricity damage as a result of lightning strike is a relatively rare condition in intensive care medicine, however it can be accompanied by high mortality and serious complications in the majority of survived patients.The objective was to demonstrate a clinical case of lightning injury and discussion of diagnostic and treatment aspects in this condition.Materials and Methods. 18-yr old patient was delivered to hospital after lightning strike. She lost consciousness, there was no breathing for a short time, and the witnesses provided artificial respiration and external cardiac co

APA, Harvard, Vancouver, ISO, and other styles

29

Socinski, Mark A., A. William Blackstock, Jeffrey A. Bogart, et al. "Randomized Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemotherapy and Dose-Escalated Thoracic Conformal Radiotherapy (74 Gy) in Stage III Non–Small-Cell Lung Cancer: CALGB 30105." Journal of Clinical Oncology 26, no. 15 (2008): 2457–63. http://dx.doi.org/10.1200/jco.2007.14.7371.

Full text

Abstract:

PurposeTo evaluate 74 Gy thoracic radiation therapy (TRT) with induction and concurrent chemotherapy in stage IIIA/B non–small-cell lung cancer (NSCLC).Patients and MethodsPatients with stage IIIA/B NSCLC were randomly assigned to induction chemotherapy with either carboplatin (area under the curve [AUC], 6; days 1 and 22) with paclitaxel (225 mg/m2; days 1 and 22; arm A) or carboplatin (AUC, 5; days 1 and 22) with gemcitabine (1,000 mg/m2; days 1, 8, 22, and 29; arm B). On day 43, arm A received weekly carboplatin (AUC, 2) and paclitaxel (45 mg/m2) while arm B received biweekly gemcitabine (3

APA, Harvard, Vancouver, ISO, and other styles

30

Villgran, Vipin Das, Aju Mathew, Margaret Quinn Rosenzweig, et al. "Effect of tumor subtype on overall survival in brain metastatic breast cancer patients treated with cranial irradiation." Journal of Clinical Oncology 32, no. 26_suppl (2014): 74. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.74.

Full text

Abstract:

74 Background: Brain metastatic breast cancer (BMBC) is often treated with whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS) or both. Breast cancer tumor subtypes defined by hormone receptor (HR) and HER2 status have an important prognostic role in metastatic disease. It is unclear if tumor subtypes have a prognostic role in patients receiving WBRT or SRS. We aimed to investigate the association between breast cancer subtype and overall survival (OS) among BMBC patients treated with WBRT and SRS. Methods: In a single-institution cohort study, BMBC patients treated with WBRT

APA, Harvard, Vancouver, ISO, and other styles

31

Duong, Hien K., Anna Koo, Lisa Rybicki, et al. "Obese Patients Have Improved Survival Following Autologous Hematopoietic Stem Cell Transplantation." Blood 120, no. 21 (2012): 1989. http://dx.doi.org/10.1182/blood.v120.21.1989.1989.

Full text

Abstract:

Abstract Abstract 1989 High-dose chemotherapy followed by autologous stem cell transplant can improve long-term outcome of patients with hematologic malignancies. Outcomes following transplant are variable. Obesity has implications for stem cell mobilization, chemotherapy administration, and medication dosing. We analyze the impact of obesity on transplant outcomes including neutrophil recovery, platelet recovery, length of hospital stay, and survival. From 1/2004 to 12/2009, 573 patients underwent autologous stem cell transplant. From these patients, 17 were excluded due to incomplete data. O

APA, Harvard, Vancouver, ISO, and other styles

32

Merryman, Reid W., Robert A. Redd, Taiga Nishihori, et al. "Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma." Blood Advances 5, no. 6 (2021): 1648–59. http://dx.doi.org/10.1182/bloodadvances.2020003556.

Full text

Abstract:

Abstract Autologous stem cell transplantation (ASCT) can be curative for patients with relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 monoclonal antibodies (mAbs) can sensitize patients to subsequent chemotherapy, we hypothesized that anti-PD-1 therapy before ASCT would result in acceptable outcomes among high-risk patients who progressed on or responded insufficiently to ≥1 salvage regimen, including chemorefractory patients who are traditionally considered poor ASCT candidates. We retrospectively identified 78 HL patients who underwent ASCT after receiv

APA, Harvard, Vancouver, ISO, and other styles

33

Gelli, Maximiliano, Jacques Ewald, Marie Laure Tanguy, et al. "Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A multicenter randomized phase II trial (PRODIGE 43 - PACHA-01)." Journal of Clinical Oncology 41, no. 16_suppl (2023): 3515. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3515.

Full text

Abstract:

3515 Background: Hepatic arterial infusion (HAI) of chemotherapy (CTx) has been proposed as a potential treatment to decrease the risk of hepatic recurrence after resection of colorectal liver metastases (CRLM). Randomized controlled trials (RCTs) led to controversial results and meta-analyses are inconclusive. We conducted a comparative phase II RCT to assess the efficacy of adjuvant HAI oxaliplatin with concomitant intravenous (IV) CTx in pts at high risk of hepatic recurrence (≥4 resected CRLM). Methods: Pts who underwent curative-intent surgery of at least 4 CRLM after preoperative IV CTx

APA, Harvard, Vancouver, ISO, and other styles

34

Conroy, T., M. Ducreux, C. Lemanski, et al. "Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): Definitive analysis of the intergroup ACCORD 03 trial." Journal of Clinical Oncology 27, no. 15_suppl (2009): 4033. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.4033.

Full text

Abstract:

4033 Background: Concomitant radiochemotherapy (CRT) is the standard treatment of LAAC. The addition of an ICT (2 cycles of 5 FU-Cisplatin) and of a higher dose of irradiation boost (HDRT) to CRT were evaluated in a factorial 2X2 arms trial (A= ICT; B=ICT+HDRT; C= Reference arm = Pelvic RT 45 Gy/25 fractions with 2 cycles of 5FU-Cisplatin and a boost of 15 Gy; D= HDRT). The aim of the study was to detect a increase from 70 to 85% of colostomy-free survival (CFS) at 3 years. Methods: 307 pts with T2 > 4 cm or T3-T4 Nx or any T, N1–3 M0 LAAC were included. Mean age was 59 y and sex-ratio was

APA, Harvard, Vancouver, ISO, and other styles

35

Afzal, Rimsha, Michelle Kim, Daniel Wahl, Theodore Lawrence, and Jamie Takayesu. "RADT-26. RADIATION FRACTIONATION IN THE MANAGEMENT OF ELDERLY PATIENTS WITH GLIOBLASTOMA BY AGE." Neuro-Oncology 26, Supplement_8 (2024): viii78. http://dx.doi.org/10.1093/neuonc/noae165.0310.

Full text

Abstract:

Abstract Multiple studies have investigated hypofractionated radiation (HFX) for elderly patients with glioblastoma (GBM), using varying age cut-offs. This leads to uncertainty about who benefits most from a hypofractionated course. This study examines the use of and outcomes with HFX, between two commonly used cut offs to define elderly GBM: 65 versus 70 years old. In this retrospective review, 309 patients diagnosed with GBM who were treated with radiation at a single academic institution were included. The Kaplan-Meier method was used to analyze overall survival. A Chi-square test was condu

APA, Harvard, Vancouver, ISO, and other styles

36

Aronova, E., G. Lukina, G. Gridneva, S. Glukhova, and A. Kudryavtseva. "AB0273 PREDICTORS OF DRUG SURVIVAL OF bDMARDS IN BIO-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS (RA) DURING THE FIRST YEAR OF THERAPY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1435.1–1435. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1140.

Full text

Abstract:

Objectives:To investigate predictors of drug survival of bDMARDs in previously bio-naive patients (pts) with RA during the first year of therapy.Methods:204 adult bio-naive pts (173 women, 84.8%), with active RA, despite the concomitant DMARD therapy, were included into retrospective study. All of them initiated bDMARDs: infliximab (INF) - 65 pts (31.9%), rituximab (RTM) - 39 (19.1%), adalimumab (ADA) - 30 (14.7%), etanercept (ETA) - 28 (13.7%), abatacept (ABA) - 23 (11.3%), tocilizumab (TZ) - 15 (7.4%), certolizumab pegol - 4 (1.9%). The following indicators were used as survival predictors:

APA, Harvard, Vancouver, ISO, and other styles

37

Menon, Sandeep, Sunil Kandiyil, Sithara Balagopal, Kadavanoor Sreejith, and Sandesh Kolassery. "Acute Kidney Injury Among Hospitalised Patients with Cirrhosis – Burden and Risk Factors." International Journal of Gastroenterology 9, no. 1 (2025): 45–53. https://doi.org/10.11648/j.ijg.20250901.18.

Full text

Abstract:

Background and Objectives: Acute Kidney Injury (AKI) in cirrhosis is a major determinant of morbidity and mortality. This study aims to assess the proportion, common predisposing factors and the mortality rate of hospitalised patients with AKI and cirrhosis. Methods: A single-center, longitudinal study was done in our setting including 186 patients with cirrhosis hospitalized to ward or ICU. AKI was diagnosed and staged as per ICA-AKI criteria. The proportion of AKI was calculated in percentage. Risk factors for AKI were recorded and their association was tested by chi-square test. Patient out

APA, Harvard, Vancouver, ISO, and other styles

38

Grelier, Laure, Michael Baboudjian, Bastien Gondran-Tellier, et al. "Stereotactic Body Radiotherapy for Frail Patients with Primary Renal Cell Carcinoma: Preliminary Results after 4 Years of Experience." Cancers 13, no. 13 (2021): 3129. http://dx.doi.org/10.3390/cancers13133129.

Full text

Abstract:

Introduction: The aim of this study was to report the oncological outcomes and toxicity of stereotactic body radiotherapy (SBRT) to treat primary renal cell carcinoma (RCC) in frail patients unfit for surgery or standard alternative ablative therapies. Methods: We retrospectively enrolled 23 patients who had SBRT for primary, biopsy-proven RCC at our tertiary center between October 2016 and March 2020. Treatment-related toxicities were defined using CTCAE, version 4.0. The primary outcome was local control which was defined using the Response Evaluation Criteria in Solid Tumors. Results: The m

APA, Harvard, Vancouver, ISO, and other styles

39

Andersson, Ellinor, Christina Swärd, Göran Stenman, Håkan Ahlman, and Ola Nilsson. "High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids." Endocrine-Related Cancer 16, no. 3 (2009): 953–66. http://dx.doi.org/10.1677/erc-09-0052.

Full text

Abstract:

Ileal carcinoids are malignant neuroendocrine tumours of the small intestine. The aim of this study was to obtain a high-resolution genomic profile of ileal carcinoids in order to define genetic changes important for tumour initiation, progression and survival. Forty-three patients with ileal carcinoids were investigated by high-resolution array-based comparative genomic hybridization. The average number of copy number alterations (CNAs) per tumour was 7.1 (range 1–22), with losses being more common than gains (ratio 1.4). The most frequent CNA was loss of chromosome 18 (74%). Other frequent C

APA, Harvard, Vancouver, ISO, and other styles

40

Lima, Roberto A., Marcos R. Tavares, Fernando L. Dias, et al. "Clinical Prognostic Factors in Malignant Parotid Gland Tumors." Otolaryngology–Head and Neck Surgery 133, no. 5 (2005): 702–8. http://dx.doi.org/10.1016/j.otohns.2005.08.001.

Full text

Abstract:

OBJECTIVE: To analyze the factors in parotid malignant epithelial tumors influencing recurrences and disease-specific survival. METHODS: We retrospectively reviewed the files of 150 patients treated at our institution, from 1974 to 1998. Twenty-four patients were not treated by surgery and were excluded from this study. The remaining 126 patients were treated with surgery and 74 patients had postoperative radiotherapy. Thirty-three patients were treated with parotidectomy plus neck dissection. Neck lymph node metastasis was found in 22 patients, 5 patients had occult neck metastasis, and 4 per

APA, Harvard, Vancouver, ISO, and other styles

41

Pavlovsky, Carolina, Santiago Pavlovsky, Maria L. Pardo, et al. "Therapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL). A Single Center Experience." Blood 108, no. 11 (2006): 4968. http://dx.doi.org/10.1182/blood.v108.11.4968.4968.

Full text

Abstract:

Abstract Purpose: To evaluate the efficacy of FCR in improving complete remission (CR), disease-free survival (DFS) and overall survival (OS) rates in patients previously treated with chlorambucil-prednisolone and untreated CLL patients. Patients and methods: A total of 45 CLL patients started FCR. Forty-one patients completed treatment: 16 following previous relapse and 25 previously untreated with progressive disease. Four patients are still receiving treatment. Median patient age was 63 years (range 34–88 years). Binet’s stage were: A: 8%, B: 34% and C: 58%. CD38 expression was positive (&a

APA, Harvard, Vancouver, ISO, and other styles

42

Bartoletti, Michele, Roberta Mazzeo, Marco De Scordilli, et al. "Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget’s disease of the vulva." International Journal of Gynecologic Cancer 30, no. 11 (2020): 1672–77. http://dx.doi.org/10.1136/ijgc-2020-001771.

Full text

Abstract:

BackgroundInvasive vulvar Paget’s disease with over-expression of the human epidermal growth factor receptor 2 (HER2) protein is potentially suitable for targeted therapy, especially in a metastatic setting where no effective treatments are available.MethodsFour consecutive patients with HER2 positive advanced vulvar Paget’s disease, treated with weekly trastuzumab (loading dose 4 mg/kg, then 2 mg/kg) and paclitaxel (80 mg/m2) followed by 3-weekly trastuzumab maintenance (6 mg/kg), are reported.ResultsMedian age and follow-up of patients were 62.5 years (45–74) and 16 months (6-54), respective

APA, Harvard, Vancouver, ISO, and other styles

43

Gururangan, Sridharan, Christina M. Cavazos, David Ashley, et al. "Phase II Study of Carboplatin in Children With Progressive Low-Grade Gliomas." Journal of Clinical Oncology 20, no. 13 (2002): 2951–58. http://dx.doi.org/10.1200/jco.2002.12.008.

Full text

Abstract:

PURPOSE: To assess the rate of tumor response and activity of carboplatin in stabilizing the growth of progressive low-grade gliomas. PATIENTS AND METHODS: Eligible patients received carboplatin 560 mg/m2 intravenously every 4 weeks for 1 year after maximum tumor response or until disease progression or unacceptable toxicity. RESULTS: Between October 1993 and October 2000, 81 children (median age, 79 months; range, 6 to 204) were enrolled onto this study. Patients received a median of 11 cycles of carboplatin (range, one to 29). Median follow-up from the time of enrollment was 55 months (range

APA, Harvard, Vancouver, ISO, and other styles

44

Fida, Madiha, Tarab Mansoor, Omar Abu Saleh, et al. "1074. Management and Outcomes of Infective Endocarditis Due to Nutritionally Variant Streptococci." Open Forum Infectious Diseases 5, suppl_1 (2018): S321—S322. http://dx.doi.org/10.1093/ofid/ofy210.911.

Full text

Abstract:

Abstract Background Nutritionally variant streptococci (NVS) are an infrequent cause of infective endocarditis (IE) and management recommendations are based on weak levels of evidence largely derived from case reports, small case series, and animal models of experimental endocarditis. Moreover, taxonomic changes have led to some confusion in designation of these organisms. Methods We retrospectively collected and analyzed data from 33 patients with NVS IE from 1970 to 2017. Only patients who met modified Duke Criteria for IE were included. Results Mean patient age was 55 years and 61% were mal

APA, Harvard, Vancouver, ISO, and other styles

45

Frontini, Luciano, Paola Candido, Maria Teresa Cattaneo, et al. "Cisplatin-Vinorelbine Combination Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer." Tumori Journal 82, no. 1 (1996): 57–60. http://dx.doi.org/10.1177/030089169608200112.

Full text

Abstract:

Aim The North Milan Group presents the results of a phase II study on a cisplatin-vinorelbine combination schedule in the treatment of locally advanced non-small cell lung cancer to evaluate its activity and tolerability. Methods Seventy-six consecutive patients entered the study. Patients’ characteristics were the following: males/females 69/7; median age, 61.4 years (range, 40-73); ECOG performance status, 0-1; 17 stage IIIa and 59 stage IIIb. There were 49 squamous cell carcinomas, 20 adenocarcinomas, and 7 large cell carcinomas. All patients had not been previously treated and showed measu

APA, Harvard, Vancouver, ISO, and other styles

46

Chandra, Sunandana, Kathleen M. Madden, Rajni Kannan, and Anna C. Pavlick. "Evaluating the safety of anti-CTLA-4 therapy in the elderly with unresectable melanoma." Journal of Clinical Oncology 31, no. 15_suppl (2013): 9063. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9063.

Full text

Abstract:

9063 Background: Anti-CTLA-4 monoclonal antibodies demonstrated an improvement in overall survival in patients with metastatic melanoma and ipilimumab (ipi) was FDA approved in 2011. We performed a retrospective analysis of 74 elderly (age ≥ 65) patients (pts) who were treated with anti-CTLA-4 therapy (tx) and evaluated their treatment related adverse events (AEs) as well as clinical response. Methods: 65 pts were treated with ipi 3 mg/kg x 4, among whom 8 pts were re-treated with ipi 3 mg/kg x 4; 3 pts were treated with ipi 10 mg/kg x 4 with 2 pts who went on to receive maintenance tx; 2 pts

APA, Harvard, Vancouver, ISO, and other styles

47

Bogani, Giorgio, Laura Matteucci, Stefano Tamberi, et al. "The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC–IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study." International Journal of Gynecologic Cancer 27, no. 9 (2017): 1856–62. http://dx.doi.org/10.1097/igc.0000000000001108.

Full text

Abstract:

ObjectivesNeoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) may be a valuable treatment option in advanced ovarian cancer when primary cytoreduction is not feasible. However, a consensus on the ideal number of NACT cycles is still lacking. In the present investigation, we aimed to evaluate how number of cycles of NACT influenced patients' outcomes.MethodsData of consecutive patients undergoing NACT and IDS were retrospectively reviewed in 4 Italian centers, and survival outcomes were evaluated.ResultsOverall, 193 patients were included. Cycles of NACT were 3, 4, and

APA, Harvard, Vancouver, ISO, and other styles

48

Proctor, Stephen J., Jennifer Wilkinson, Gail Jones, et al. "Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study." Blood 119, no. 25 (2012): 6005–15. http://dx.doi.org/10.1182/blood-2011-12-396556.

Full text

Abstract:

Abstract The SHIELD program for Hodgkin lymphoma in patients 60 years of age or older, prospectively evaluated clinical features and outcome in a large patient cohort (n = 175). The central element was a phase 2 study of VEPEMB chemotherapy (n = 103, median age 73 years) incorporating comorbidity assessment. A total of 72 other patients were treated off-study but registered prospectively and treated concurrently with: ABVD (n = 35); CLVPP (n = 19), or other (n = 18). Of VEPEMB patients, 31 had early-stage disease (stage 1A/2A) and received VEPEMB 3 times plus radiotherapy. Median follow-up was

APA, Harvard, Vancouver, ISO, and other styles

49

Carceller, Fernando, Francisco Bautista, Alicia Castañeda, et al. "Mortality and survival rates in children and adolescents enrolled in early phase trials with a dose-finding/dose-confirmation component: An innovative therapies for children with cancer (ITCC) study." Journal of Clinical Oncology 37, no. 15_suppl (2019): e21509-e21509. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e21509.

Full text

Abstract:

e21509 Background: Participation of children with advanced solid cancers in phase I trials raises ethical and logistic dilemmas. Life-expectancy beyond 8-12 weeks is a common inclusion criterion, but it can be difficult to gauge. This multicentric European study assessed the mortality and survival rates in pediatric phase I trials. Methods: Retrospective study of patients aged < 18 years with solid tumors enrolled in phase I trials in ITCC centres between 2015-2017. Outcome variables were described and prognostic factors analysed. Results: 256 patients across 12 centres in 5 countries were

APA, Harvard, Vancouver, ISO, and other styles

50

He, Ruojie, Minying Zheng, Ling Lian, and Xiaoli Yao. "Milano–Torino Staging and Long-Term Survival in Chinese Patients with Amyotrophic Lateral Sclerosis." Cells 10, no. 5 (2021): 1220. http://dx.doi.org/10.3390/cells10051220.

Full text

Abstract:

(1) Background: The aim of this longitudinal study was to evaluate the association between disease progression according to the Milano–Torino staging (MITOS) system and long-term survival in Chinese patients with amyotrophic lateral sclerosis (ALS). We also examined factors affecting MITOS progression. (2) Methods: Patients were enrolled and underwent follow-up at 6, 12, 18, and 24 months, and their demographic and clinical data, including the Milano–Torino stage, Amyotrophic Lateral Sclerosis Functional Rating Scale—Revised (ALSFRS-R) score and neuropsychiatric data, were evaluated. The sensi

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!